ANZCTR search results

The study aims to determine if supplementation with fish oils or the vitamin coenzyme Q10, or a combination of both, will lead to beneficial effects on blood pressure and heart disease risk in patients with renal impairment. Heart disease is one of the main causes of death in Australia. People with renal impairment are at increased cardiovascular risk due to the coexistence of hypertension (high blood pressure), blood lipid abnormalities (blood fats) and increased inflammation. One approach may be to complement drug treatment of renal impairment with non-drug measures such as nutrition and lifestyle factors. In this regard, fish oils have great clinical potential in the treatment of renal impairment and its associated complications. Fish oils reduce blood pressure and improve blood vessel wall elasticity. They improve blood fats, reduce the tendency of blood to clot and reduce inflammation. Coenzyme Q10 is a vitamin that plays a critical role in cell function. It improves blood pressure, blood vessel and heart function, and glucose control.

Subjects randomly allocated to receive either active, aggressive diet and exercise program or simple information sheet only, for 4 months

Sleep studies on 4 consecutive nights, 2 in-lab, 2 at-home, in random order

For pain relief after VATS pleurodesis, patients are given either Celebrex or Placebo for 5 days plus any other required analgesics. We aim to determine whether there is any difference in failure of the lung to adhere to the lining of the chest.

To determine whether a new form of minimally invasive ("keyhole") surgery results in less pain and suffering than traditional surgery of the lung via thoracotomy.

90 volunteers presenting for treatment at a public hospital outpatient department with restricted, painful shoulder dysfunction will be recruited. Following an initial examination to obtain baseline data subjects will be randomly allocated to one of two treatment groups: advice and exercises or advice, exercises and passive joint mobilisations. Subjects will attend between 4 and 8 treatment sessions over a one month period. Outcome measurements will then be re-assessed. Following re-assessment treatment may continue for a maximum of 10 treatment sessions over a maximum of 8 weeks. Re-assessment will be repeated 6 months after recruitment.